Dr. Reddy's Laboratories
Search results
Jun 24, 2024 · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics
Jun 24, 2024 · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
Nov 29, 2022 · Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
Biocon Biologics Limited (BBL) is a subsidiary of the publicly listed Biocon Limited, which operates its biosimilars business through BBL. Please refer to the Investors’ Section of Biocon Limited for all statutory information.
Sep 6, 2023 · Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars...
May 28, 2023 · Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league.
